MA33166B1 - Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose - Google Patents
Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibroseInfo
- Publication number
- MA33166B1 MA33166B1 MA33582A MA33582A MA33166B1 MA 33166 B1 MA33166 B1 MA 33166B1 MA 33582 A MA33582 A MA 33582A MA 33582 A MA33582 A MA 33582A MA 33166 B1 MA33166 B1 MA 33166B1
- Authority
- MA
- Morocco
- Prior art keywords
- fibrosis
- treatment
- formula
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 4
- 230000004761 fibrosis Effects 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne l'utilisation de pyrimidylaminobenzamides de formule (I) où les radicaux ont les significations comme présentement définies, ou d'un sel pharmaceutiquement acceptable de ceux-ci pour la fabrication de compositions pharmaceutiques pour utilisation dans le traitement de la fibrose, l'utilisation de pyrimidylaminobenzamides de formule (I) ou d'un sel pharmaceutiquement acceptable de ceux-ci dans le traitement de la fibrose, un procédé de traitement d'animaux à sang chaud comprenant des humains souffrant de fibrose par administration audit animal nécessitant un tel traitement d'une dose efficace d'un pyrimidylaminobenzamide de formule I ou un sel pharmaceutiquement acceptable de celui-ci, et des combinaisons comprenant (a) au moins un pyrimidylaminobenzamide de formule (I) et (b) au moins un composé choisi parmi des antagonistes de récepteur AT
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08160366 | 2008-07-14 | ||
| PCT/EP2009/058940 WO2010007034A1 (fr) | 2008-07-14 | 2009-07-14 | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33166B1 true MA33166B1 (fr) | 2012-04-02 |
Family
ID=39765085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33582A MA33166B1 (fr) | 2008-07-14 | 2009-07-14 | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20110124670A1 (fr) |
| EP (1) | EP2300014A1 (fr) |
| JP (1) | JP2011528015A (fr) |
| KR (1) | KR20110051194A (fr) |
| CN (1) | CN102099039A (fr) |
| AU (1) | AU2009272814A1 (fr) |
| BR (1) | BRPI0915905A2 (fr) |
| CA (1) | CA2730225A1 (fr) |
| CL (1) | CL2011000073A1 (fr) |
| IL (1) | IL210290A0 (fr) |
| MA (1) | MA33166B1 (fr) |
| MX (1) | MX2011000511A (fr) |
| NZ (1) | NZ590177A (fr) |
| RU (1) | RU2011105059A (fr) |
| TW (1) | TW201006823A (fr) |
| WO (1) | WO2010007034A1 (fr) |
| ZA (1) | ZA201009153B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150098993A1 (en) * | 2011-07-28 | 2015-04-09 | Shireen Vali | Compositions, process of preparation of said compositions and method of treating inflammatory diseases |
| RU2014146993A (ru) * | 2012-04-24 | 2016-06-10 | Чугаи Сейяку Кабусики Кайся | Производное хиназолиндиона |
| MX2014012991A (es) | 2012-04-24 | 2015-08-14 | Chugai Pharmaceutical Co Ltd | Derivado de benzamida. |
| CN103965195B (zh) * | 2013-02-01 | 2016-09-28 | 中国科学院广州生物医药与健康研究院 | 用于盘状结构域受体小分子抑制剂的化合物及其应用 |
| CA2927830A1 (fr) | 2013-10-23 | 2015-04-30 | Chugai Seiyaku Kabushiki Kaisha | Derive de quinazolinone et d'isoquinolinone |
| CN106282033A (zh) * | 2016-08-15 | 2017-01-04 | 郑毅男 | 一株新青霉菌及其代谢产物安他拟酸a |
| KR102914830B1 (ko) * | 2019-10-15 | 2026-01-19 | 재단법인 한국파스퇴르연구소 | 2-메톡시에스트라디올 유도체 및 이들의 의약 용도 |
| CN115010720B (zh) * | 2022-06-02 | 2023-08-11 | 中国科学院昆明植物研究所 | 中甸艾中倍半萜二聚体及其药物组合物与其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002210925A1 (en) * | 2000-10-25 | 2002-05-06 | Takeda Chemical Industries Ltd. | Preventives/remedies for portal hypertension |
| DK1487424T3 (da) * | 2002-03-15 | 2007-01-08 | Novartis Ag | 4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl)-pyrimidin-2-yl-amino)phenyl-benzamid til behandling af Ang II-medierede sygdomme |
| CA2580266A1 (fr) * | 2004-10-08 | 2006-04-20 | Novartis Ag | Combinaison de composes organiques |
| WO2007022041A2 (fr) * | 2005-08-11 | 2007-02-22 | Novartis Ag | Mutations et polymorphismes de l'hdac3 |
| WO2007051862A1 (fr) * | 2005-11-07 | 2007-05-10 | Novartis Ag | Combinaison de composés organiques |
| US8093259B2 (en) * | 2006-05-25 | 2012-01-10 | Novartis Ag | 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma |
| WO2008027284A1 (fr) * | 2006-08-25 | 2008-03-06 | Novartis Ag | Dérivés d'imidazole fusionnés destinés à traiter les troubles médiés par l'aldostérone synthase et/ou par 11-beta-hydroxylase et/ou aromatase |
| JP5220025B2 (ja) * | 2006-12-04 | 2013-06-26 | プロメディオール, インコーポレイテッド | 線維症疾患を処置するための併用療法 |
| KR20090090395A (ko) * | 2006-12-18 | 2009-08-25 | 노파르티스 아게 | 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도 |
| WO2008076862A2 (fr) * | 2006-12-18 | 2008-06-26 | Novartis Ag | Composés organiques |
-
2009
- 2009-07-13 TW TW098123638A patent/TW201006823A/zh unknown
- 2009-07-14 CA CA2730225A patent/CA2730225A1/fr not_active Abandoned
- 2009-07-14 JP JP2011517892A patent/JP2011528015A/ja active Pending
- 2009-07-14 EP EP09797487A patent/EP2300014A1/fr not_active Withdrawn
- 2009-07-14 MX MX2011000511A patent/MX2011000511A/es not_active Application Discontinuation
- 2009-07-14 BR BRPI0915905A patent/BRPI0915905A2/pt not_active IP Right Cessation
- 2009-07-14 NZ NZ590177A patent/NZ590177A/xx not_active IP Right Cessation
- 2009-07-14 CN CN2009801273499A patent/CN102099039A/zh active Pending
- 2009-07-14 WO PCT/EP2009/058940 patent/WO2010007034A1/fr not_active Ceased
- 2009-07-14 US US13/054,011 patent/US20110124670A1/en not_active Abandoned
- 2009-07-14 MA MA33582A patent/MA33166B1/fr unknown
- 2009-07-14 RU RU2011105059/15A patent/RU2011105059A/ru unknown
- 2009-07-14 AU AU2009272814A patent/AU2009272814A1/en not_active Abandoned
- 2009-07-14 KR KR1020117003226A patent/KR20110051194A/ko not_active Withdrawn
-
2010
- 2010-12-20 ZA ZA2010/09153A patent/ZA201009153B/en unknown
- 2010-12-27 IL IL210290A patent/IL210290A0/en unknown
-
2011
- 2011-01-13 CL CL2011000073A patent/CL2011000073A1/es unknown
-
2013
- 2013-06-06 US US13/911,127 patent/US20130267549A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201006823A (en) | 2010-02-16 |
| RU2011105059A (ru) | 2012-08-20 |
| AU2009272814A1 (en) | 2010-01-21 |
| US20110124670A1 (en) | 2011-05-26 |
| CL2011000073A1 (es) | 2011-07-15 |
| BRPI0915905A2 (pt) | 2018-02-20 |
| ZA201009153B (en) | 2011-11-30 |
| US20130267549A1 (en) | 2013-10-10 |
| NZ590177A (en) | 2012-12-21 |
| JP2011528015A (ja) | 2011-11-10 |
| WO2010007034A1 (fr) | 2010-01-21 |
| IL210290A0 (en) | 2011-03-31 |
| MX2011000511A (es) | 2011-02-24 |
| CN102099039A (zh) | 2011-06-15 |
| CA2730225A1 (fr) | 2010-01-21 |
| EP2300014A1 (fr) | 2011-03-30 |
| KR20110051194A (ko) | 2011-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2370495C2 (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
| MA47079A (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
| EA201000024A1 (ru) | Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1 | |
| MA37834A1 (fr) | Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| EP1857457A3 (fr) | Dérivé de benzimidazole et son utilisation comme antagoniste du récepteur AII | |
| MXPA05011166A (es) | Antagonistas del receptor del peptido relacionado con el gen de la calcitonina. | |
| MA31766B1 (fr) | Composés organiques | |
| MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
| MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
| MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
| WO2009106980A3 (fr) | Dérivés d'indazole | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| MXPA05008142A (es) | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension. | |
| EA201001094A1 (ru) | Производные индазола | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
| MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
| MA29335B1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| NO20073170L (no) | Kaspaseinhibitorer og anvendelse derav | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique |